Upregulation of transient receptor potential melastatin 6 channel expression by rosiglitazone and all ‐trans‐retinoic acid in erlotinib‐treated renal tubular epithelial cells

Rosiglitazone and all ‐trans‐retinoic acid (ATRA) increased transient receptor potential melastatin 6 (TRPM6) expression in renal tubular epithelial cells. Rosiglitazone and ATRA increased Mg2+ influx. Rosiglitazone and ATRA may reverse the reduction in Mg2+ reabsorption caused by antiepidermal growth factor receptor (anti ‐EGFR) drugs. AbstractAnti ‐epidermal growth factor receptor (EGFR) drugs including erlotinib cause a side effect of hypomagnesemia. In lung adenocarcinoma A549 cells, anticancer agents such as cisplatin and doxorubicin dose‐dependently increased toxicity, but the effects were significantly suppressed by culturing the cel ls in low Mg2+‐containing media. To obtain the maximum effect in cancer chemotherapy, it should be necessary to prevent the reduction of body Mg2+ content. Anti ‐EGFR drugs inhibit EGF‐induced elevation of transient receptor potential melastatin 6 (TRPM6) Mg2+ channel in renal tubular epithelial NRK ‐52E cells. Here, we found that rosiglitazone, an antidiabetic drug, and all‐trans‐retinoic acid (ATRA), a vitamin A derivative, increase the messenger RNA (mRNA) level of TRPM6 in the presence of erlotinib. The rosiglitazone‐ and ATRA‐induced elevation of mRNA level, Mg2+ influx, and promoter activity of TRPM6 were inhibited by GW ‐9662, a potent antagonist of peroxisome proliferator‐activated receptor (PPAR)γ, and LE135, a retinoic acid receptor (RAR) antagonist, respectively. Rosiglitazone increased the phospho...
Source: Journal of Cellular Physiology - Category: Cytology Authors: Tags: ORIGINAL RESEARCH ARTICLE Source Type: research